DOCSLIB.ORG

Author Index Volume 142

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Author Index Volume 142 AUTHOR INDEX VOLUME 142 Achtman, Mark, 285 Cantu, Mona, 899 Faelen, Michel, 391 Akhmedov, A. T., 322 Carlsson, Jan, 319 Fairweather, Neil F., 153 Alberghina, Lilia, 268 Carlton, Bruce C., 508 Farmer, K. Sam, 347 Albersheim, Peter, 243 Carman, George M., 262 Felton, Jeffrey, 221 Alfredsson, G. A., 486 Carothers, Adelaide M., 174, 185 Ferenci, Thomas, 521 Ali Khan, M. Yousufuddin, 786 Carpenter, Vincent S., 319 Ferro, Adolph J., 608 Amaro, Ana M., 355 Carty, C. E., 1040 Ferry, J. G., 800 Apel, William A., 295 Castets, Anne-Marie, 310 Finnerty, W. R., 859 Apirion, David, 359 Chang, Chung Nan, 726 Fontana, R., 43 Archer, David B., 694 Chang, Robin, 1025 Foster, John W., 1032 Arima, Kei, 315 Chapman, Virginia, 982 Fowler, Audree V., 732 Arnuad, Maryvonne, 1045 Chater, Keith F., 8 Frankel, Alan D., 335 Arp, Daniel J., 138 Chatterjee, Arun K., 111 Frenz, Joachim, 162 Chiang, Shu-Jen, 668 Freundt, E. A., 683 Banner, Carl D. B., 90 Choung, Kyung K. L., 513 Fried, Victor A., 1036 Barbour, Michael G., 480 Chute, Hilary T., 621 Friedberg, Ilan, 651 Barker, David, 1025 Clark, Alvin J., 701 Friedman, Eliot L., 344 Barrera, Cecilio R., 1029 Clowes, Royston C., 668 Frunzio, Rodolfo, 32 Baskowsky-Foster, Anne M., Cohen, Lawrence K., 380 Fultz, Patricia N., 513 1032 Cohen-Bazire, Germaine, 310 Bayly, Ronald C., 480 Cohn, Murray S., 791 Garcia, Ernesto, 229 Becker, Gerald W., 747 Cornett, James B., 741 Garcia, J. Roberto, 196 Beckwith, Jon, 726 Corral, Javier, 1029 Gardner, Jeffrey F., 380 Beckwith, Jon R., 732 Gayda, D. J., 556 Bekker, M. L., 322 Cox, Charles D., 581 Cox, John C., 908 George, Jacqueline, 819 Bellion, Edward, 786 Gest, Howard, 908 Benedict, Charles D., 60 Cramer, Carole L., 945 Crandall, Marjorie, 276 Goelz, Susan, 362 Benson, David R., 138 Goldberg, Ivan D., 350 Beppu, Teruhiko, 315 Crisona, Nancy J., 701 Cronan, John E., Jr., 362 Goldberg, Richard B., 99 Berg, Douglas E., 439 Goldenbaum, Paul E., 347 Berger, B., 1040 Crossland, Lyle, 439 Beutin, Lothar, 285 Cryz, Stanley J., 836 Beveridge, T. J., 302 Cundliffe, Eric, 455 Haldenwang, William G., 90 Birenbaum, Mark, 327 Hall, Barry G., 433, 1036 Bjork, Glenn R., 371 Dagley, Stanley, 916 Halvorson, Harlyn O., 1045 Blasi, Francesco, 32 D'Ari, Richard, 819 Hanson, Barbara A., 79 Blazey, D. L., 1015 Hantke, Klaus, 162 Darvill, Alan G., 243 Harrington, Charles R., 852 Blumenthal, Robert M., 202, DasSarma, Shiladitya, 992 1049 Hartman, Philip E., 335 Davis, Rowland H., 945 Hashimoto, Hajime, 145 Bof, Mireille, 768 DeLong, Sara, 982 Bohnhoff, Marjorie, 344 Heincz, Maria C., 185 Dennis, Patrick P., 202, 1049 Hepburn, Michael L., 236 Boschwitz, Hasia, 1045 DeVoe, I. W., 879 Botta, G., 43 Hiatt, William R., 196 Braun, Volkmar, 162 Dickson, Robert C., 776 Hitchcock, Michael J. M., 424 Brawley, James V., 608 Donachie, W. D., 615 Hoch, James A., 90 Brennan, Edward F., 729 Donnelly, Mark I., 916 Hodgson, Brian, 424 Brown, Barbara J., 508 Douglas, L. Julia, 852 Holland, I. Barry, 153 Brown, C. M., 486 Dow, J. Maxwell, 939 Holmes, M., 254 Bruni, Carmelo B., 32 Dudek, Edward J., 344 Hoogenraad, Nicholas J., 720 Bruskin, Arthur M., 755 Dugan, Patrick R., 295 Hopper, David J., 21 Bryant, Julia E., 131 Duncan, Bruce K., 335 Horwitz, Arnold H., 659 Burgess, Jeremy, 973 Dworkin, M., 1007 Huisman, Olivier, 819 Burns, R. O., 1015 Humbert, Richard, 212 Burns, R. H., 138 Egan, Patricia A., 621 Hynes, Michael J., 400 Engel, H. W. B., 407 Campbell, Allan, 1025 Ensley, Burt D., Jr., 859 Iglewski, Barbara H., 836 Canepari, P., 43 Espionsa, Manolo, 229 Ingram, L. O., 1040 ii AUTHOR INDEX J. BACTERIOL. Inouye, Hiroshi, 726 McNeil, Michael, 243 Sargent, Michael G., 491 Ishii, Junko, 27, 735 Medina, Angelica, 249 Satre, Michel, 768 Michaelis, Susan, 221 Satta, G., 43 Jacobson, Lewis A., 888 Millar, Sharon, 1004 Scaife, J. G., 462 Jaskunas, S. Richard, 992 Misra, Tapan K., 359 Schaller, Klaus, 162 Jen-Jacobson, Linda, 888 Mitchell, Thomas G., 714 Schauer, N. L., 800 Carlos 355 Mitsuhashi, Susumu, 145 Schekman, Randy, 414 Jerez, A., Mock, Michele, 384 Schleiss, M., 639 Model, Peter, 726 Schlessinger, David, 327 Kaback, H. Ronald, 651 Moran, Charles P., Jr., 331 Schnaitman, Carl A., 1019 Kaboev, 0. K., 322 Morandi, Carlo, 659 Schwartz, Maxime, 384 Kainuma-Kuroda, Ritsu, 362 Morello, Josephine A., 344 Schwentorat, Marina, 521 Kameyama, Tadanori, 366 Murgola, Emanuel J., 131 Scott, Janet H., 414 Kaplan, Samuel, 380 Murphey-Corb, Michael, 191 Shizuya, Hiroaki, 1004 Kemp, Paul D., 21 Murray, Michael L., 191 Shockman, Gerald D., 741 Kemper, Jost, 513 Murray, Noreen E., 962 Shropshire, W., Jr., 1023 Ketner, Gary, 1025 Musti, Anna M., 32 Shungu, Daniel L., 741 Keynan, Alex, 1045 Siemens, Teresa V., 499 King, Steven R., 992 Nagaishi, Haruko, 701 Simoni, Robert D., 212 Knackmuss, Hans-Joachim, 467 Simons, Robert W., 621 Kominski, Gerald, 344 Nakae, Taiji, 27, 735 Nakayama, Hiroaki, 1010 Skold, Ola, 1 Kondoh, Hisato, 527 Skoropad, William P., 689 Kong, Hay-Long, 191 Nichols, Diane L., 499 Niimi, Kyoko, 1010 Smith, B. A., 1007 Kooistra, Jan, 829 Smith, F. J., 556 Kozloff, Lloyd M., 982 Niimi, Masakazu, 1010 Niven, Donald F., 603 Smith, J. M., 556 Kubitschek, H. E., 724 Soedirman, N., 407 Kuemmerle, Nancy B., 535 Noti, J. D., 556 Nowak, Jan A., 701 Sonenshein, Abraham L., 90, 331 Kuwano, Michihiko, 325 Staskawicz, Brian J., 474, 720 Kwon-Chung, Kyung J., 15 Nunn, William D., 621 Ny, Tor, 371 Steinberg, Valerie I., 350 Stephens, Karen, 1023 Lamba, Parveen, 169 Stewart, Murray, 302 Lawrence, L. J., 276 O'Connor, Michael B., 90 Streicher, Stanley L., 69 Leathers, T. D., 556 Ohman, Dennis E., 836 Stuy, Johan H., 925 Leduc, Mireille, 52 Ohnishi, Yoshinari, 327 Suarez, Juan E., 8 Lee, David R., 1019 Old, D. C., 486 Subrahmanyam, C. S., 547, 556 Leefeldt, R. H., 645 Ollington, James F., 90 Sueoka, Noboru, 339 Leonardo, James M., 99 Ono, Mayumi, 325 153 Swedberg, Gote, 1 Lerner, Stephen A., 344 Orr, Elisha, Sypherd, Paul S., 196 Lester, Robert L., 79, 747 Ozaki, Akio, 315 Levi, Marisa, 268 Linforth, John L., 424 Palchaudhuri, Sunil, 174 Tabor, Celia White, 791 Lopez, Paloma, 229 Panopoulos, Nickolas J., 474, 720 Tabor, Herbert, 791 Lord, Peter G., 808 Parkinson, John S., 953 Tandeau de Marsac, Nicole, 310 Losick, Richard, 90, 331 Perez, R. C., 639 Tatum, Edward L., 763 Luchkina, L. A., 322 Perez, Rachel C., 633 Tecoma, Evelyn S., 931 Lutkenhaus, J. F., 615 Peters, Julius, 196 Tewari, Jalpa P., 689 Lynn, Steven P., 380 Pierucci, O., 254 Thompson, Jill, 455 Plaskitt, Kitty A., 694, 973 Tokunaga, Junichi, 1010 Toussaint, Ariane, 391 MacLeod, Robert A., 603 Pogue-Geile, Kay L., 992 Polacheck, Itzhack, 15 Townsend, Rod, 694, 973 Madigan, Michael T., 908 Trezzi, Federica, 268 Mahler, Inga, 1045 Trueba, Frank J., 869 Malhotra, Sudarshan K., 689 Rand, James B., 763 Tuttle, Jon H., 295 Manning, Marcia, 714 Ranhand, Jon M., 568 Tyler, Bonnie, 69 Manning, Paul A., 285 Ray, Paul H., 60 Mardones, Elvira, 355 Reid, Graham C., 447 Markin, Jennifer S., 776 Reineke, Walter, 467 Ullrich, Susanne, 521 Marsh, Robert C., 236 Rickert, M., 254 Umbarger, H. E., 547, 556 Martegani, Enzo, 268 Robb, Frank T., 447 Uozumi, Takeshi, 315 Masker, Warren E., 535 Rocha, Victor, 729 Urefia, Maria T. Perez, 229 Matin, A., 639, 645 Roehl, R. A., 120 Matin, Abdul, 633 Rolseth, Susan J., 1036 Valdes, Francisco, 249 Matsuda, Motoo, 366 Romano, Antonio H., 755 van Embden, J. D. A., 407 McCorkle, George M., 547 Romano, Michael J., 786 van Heijenoort, Jean, 52 McFall, Elizabeth, 174, 185 Rost, J. A., 407 van Leeuwen, W. J., 407 VOL. 142, 1980 AUTHOR INDEX iii Vaughn, Lynn E., 945 Watson, Martin D., 462 Wright, Andrew, 221 Venema, Gerard, 829 Webster, Dale A., 169 Wu, David, 931 Vicufia, Rafael, 249 Weiss, Alison, 439 Vignais, Pierre V., 768 Welply, Joseph K., 732 Yamamori, Tetsuo, 843 Villa, Vicente D., 939 Wheals, Alan E., 808 Yoch, Duane C., 899 521 White, David, 1023 York, William S., 243 Vilmart, Jeannine, E. K. C., 879 R. T., 120 Wieczorek, Donna S., 262 Yu, Vinopal, Wilcox, Gary, 659 Yudelevich, Arturo, 249 Vinther, O., 683 Winston, Scott, 339 Yura, Takashi, 843 Voytek, Anna, 755 Woldringh, Conrad L., 869 Wolf, Richard E., Jr., 588 Zabin, Irving, 732 Ward, Douglas, F., 962 Wolf-Watz, Hans, 615 Zitomer, Richard S., 499 Watanabe, Haruo, 145 Woods, David R., 447 Zorzopulos, Jorge, 982 SUBJECT INDEX VOLUME 142 Acetohydroxy acid synthetase a-Aminoisobutyrate transport N. gonorrhoeae, absence in clinical isolate of, 334 A. haloplanktis, 603 Acinetobacter sp. HO1-N sodium ion-substrate symport, 603 cytochromes, 859 ams electron transport, 859 E. coli, 325 Actinorhizal root nodules and root nodule homoge- mRNA longevity, 325 nates Antigens A. glutinosa, 138 M. gallisepticum membranes, 683 A. rhombifolia, 138 araBAD promoter mutants A. rubra, 138 DNA sequence, 659 hydrogenase, 138 E. coli, 659 M. pensylvanica, 138 Ascospore germination Adenosine 5'-triphosphate formation S-adenosylmethionine, 608 T. ferrooxidans vesicles, 295 S. cerevisiae, 608 Adenosine triphosphatase asn aurovertin, 768 asparagine auxotrophy, 221 citreoviridin, 768 E. coli, 221 E. coli, 768 asnA S-Adenosylmethionine asparagine synthetase, 212 ascospore germination, 608 E. coli, 212 M. racemosus morphogenesis, 196 asnB S. cerevisiae, 608 asparagine synthetase, 212 Adenylate energy charge E. coli, 212 M. xanthus, 1007 Asparagine auxotrophy Albugo candida asn genes, 221 cell wall surface layer, 689 E. coli, 221 lamellae, 689 Asparagine synthetase Alcohol asnA, 212 E. coli, 1040 asnB, 212 phospholipid, 1040 E. coli, 212 Alkaline phosphatase precursor Aspartokinase E. coli inner membrane preparation, 726 B. brevis, 424 processing to mature enzyme, 726 lysine inhibitable, 424 Alnus glutinosa lysine-plus-threonine inhibitable, 424 hydrogenase in root nodules, 138 Aspergillus nidulans Alnus rhombifolia amd-205, 400 hydrogenase in root nodules, 138 amdI93, 400 Alnus rubra o-amino acid induction, 400 hydrogenase in root nodules, 138 mutation defmiing site of action of gene amdR, 400 Alteromonas haloplanktis Asymmetrical division a-aminoisobutyrate transport, 603 S.
Load more

Recommended publications
  • Review on Plant Antimicrobials: a Mechanistic Viewpoint Bahman Khameneh1, Milad Iranshahy2,3, Vahid Soheili1 and Bibi Sedigheh Fazly Bazzaz3*
    Khameneh et al. Antimicrobial Resistance and Infection Control (2019) 8:118 https://doi.org/10.1186/s13756-019-0559-6 REVIEW Open Access Review on plant antimicrobials: a mechanistic viewpoint Bahman Khameneh1, Milad Iranshahy2,3, Vahid Soheili1 and Bibi Sedigheh Fazly Bazzaz3* Abstract Microbial resistance to classical antibiotics and its rapid progression have raised serious concern in the treatment of infectious diseases. Recently, many studies have been directed towards finding promising solutions to overcome these problems. Phytochemicals have exerted potential antibacterial activities against sensitive and resistant pathogens via different mechanisms of action. In this review, we have summarized the main antibiotic resistance mechanisms of bacteria and also discussed how phytochemicals belonging to different chemical classes could reverse the antibiotic resistance. Next to containing direct antimicrobial activities, some of them have exerted in vitro synergistic effects when being combined with conventional antibiotics. Considering these facts, it could be stated that phytochemicals represent a valuable source of bioactive compounds with potent antimicrobial activities. Keywords: Antibiotic-resistant, Antimicrobial activity, Combination therapy, Mechanism of action, Natural products, Phytochemicals Introduction bacteria [10, 12–14]. However, up to this date, the Today’s, microbial infections, resistance to antibiotic structure-activity relationships and mechanisms of action drugs, have been the biggest challenges, which threaten of natural compounds have largely remained elusive. In the health of societies. Microbial infections are responsible the present review, we have focused on describing the re- for millions of deaths every year worldwide. In 2013, 9.2 lationship between the structure of natural compounds million deaths have been reported because of infections and their possible mechanism of action.
    [Show full text]
  • Mechanism of Action of Pefloxacin on Surface Morphology, DNA Gyrase Activity and Dehydrogenase Enzymes of Klebsiella Aerogenes
    African Journal of Biotechnology Vol. 10(72), pp. 16330-16336, 16 November, 2011 Available online at http://www.academicjournals.org/AJB DOI: 10.5897/AJB11.2071 ISSN 1684–5315 © 2011 Academic Journals Full Length Research Paper Mechanism of action of pefloxacin on surface morphology, DNA gyrase activity and dehydrogenase enzymes of Klebsiella aerogenes Neeta N. Surve and Uttamkumar S. Bagde Department of Life Sciences, Applied Microbiology Laboratory, University of Mumbai, Vidyanagari, Santacruz (E), Mumbai 400098, India. Accepted 30 September, 2011 The aim of the present study was to investigate susceptibility of Klebsiella aerogenes towards pefloxacin. The MIC determined by broth dilution method and Hi-Comb method was 0.1 µg/ml. Morphological alterations on the cell surface of the K. aerogenes was shown by scanning electron microscopy (SEM) after the treatment with pefloxacin. It was observed that the site of pefloxacin action was intracellular and it caused surface alterations. The present investigation also showed the effect of Quinolone pefloxacin on DNA gyrase activity of K. aerogenes. DNA gyrase was purified by affinity chromatography and inhibition of pefloxacin on supercoiling activity of DNA gyrase was studied. Emphasis was also given on the inhibition effect of pefloxacin on dehydrogenase activity of K. aerogenes. Key words: Pefloxacin, Klebsiella aerogenes, scanning electron microscopy (SEM), deoxyribonucleic acid (DNA) gyrase, dehydrogenases, Hi-Comb method, minimum inhibitory concentration (MIC). INTRODUCTION Klebsiella spp. is opportunistic pathogen, which primarily broad spectrum activity with oral efficacy. These agents attack immunocompromised individuals who are have been shown to be specific inhibitors of the A subunit hospitalized and suffer from severe underlying diseases of the bacterial topoisomerase deoxyribonucleic acid such as diabetes mellitus or chronic pulmonary obstruc- (DNA) gyrase, the Gyr B protein being inhibited by tion.
    [Show full text]
  • Advances in Antimicrobial Resistance Monitoring Using Sensors and Biosensors: a Review
    chemosensors Review Advances in Antimicrobial Resistance Monitoring Using Sensors and Biosensors: A Review Eduardo C. Reynoso 1 , Serena Laschi 2, Ilaria Palchetti 3,* and Eduardo Torres 1,4 1 Ciencias Ambientales, Instituto de Ciencias, Benemérita Universidad Autónoma de Puebla, Puebla 72570, Mexico; [email protected] (E.C.R.); [email protected] (E.T.) 2 Nanobiosens Join Lab, Università degli Studi di Firenze, Viale Pieraccini 6, 50139 Firenze, Italy; [email protected] 3 Dipartimento di Chimica, Università degli Studi di Firenze, Via della Lastruccia 3, 50019 Sesto Fiorentino, Italy 4 Centro de Quìmica, Benemérita Universidad Autónoma de Puebla, Puebla 72570, Mexico * Correspondence: ilaria.palchetti@unifi.it Abstract: The indiscriminate use and mismanagement of antibiotics over the last eight decades have led to one of the main challenges humanity will have to face in the next twenty years in terms of public health and economy, i.e., antimicrobial resistance. One of the key approaches to tackling an- timicrobial resistance is clinical, livestock, and environmental surveillance applying methods capable of effectively identifying antimicrobial non-susceptibility as well as genes that promote resistance. Current clinical laboratory practices involve conventional culture-based antibiotic susceptibility testing (AST) methods, taking over 24 h to find out which medication should be prescribed to treat the infection. Although there are techniques that provide rapid resistance detection, it is necessary to have new tools that are easy to operate, are robust, sensitive, specific, and inexpensive. Chemical sensors and biosensors are devices that could have the necessary characteristics for the rapid diag- Citation: Reynoso, E.C.; Laschi, S.; nosis of resistant microorganisms and could provide crucial information on the choice of antibiotic Palchetti, I.; Torres, E.
    [Show full text]
  • Challenges of Antibacterial Discovery Lynn L
    CLINICAL MICROBIOLOGY REVIEWS, Jan. 2011, p. 71–109 Vol. 24, No. 1 0893-8512/11/$12.00 doi:10.1128/CMR.00030-10 Copyright © 2011, American Society for Microbiology. All Rights Reserved. Challenges of Antibacterial Discovery Lynn L. Silver* LL Silver Consulting, LLC, 955 S. Springfield Ave., Unit C403, Springfield, New Jersey 07081 INTRODUCTION .........................................................................................................................................................72 The Discovery Void...................................................................................................................................................72 Class Modifications versus Novel Classes.............................................................................................................72 BACKGROUND............................................................................................................................................................72 Early Screening—a Brief and Biased Philosophical History .............................................................................72 The Rate-Limiting Steps of Antibacterial Discovery ...........................................................................................74 The Multitarget Hypothesis ....................................................................................................................................74 ANTIBACTERIAL RESISTANCE ..............................................................................................................................75
    [Show full text]
  • 539 A2062 516 A83016F 445 Acidic Phospholipids 187
    539 Index a aminobenzimidazole ureas 282 A2062 516 aminocoumarins 17, 19–20, 86, 87, A83016F 445 276–280, 284 acidic phospholipids 187 aminoglycoside acetyltransferases (AACs) acitretin 358, 364, 365 83–84, 461 actinonin 412, 415, 417–418 aminoglycoside phosphotransferases (APHs) acyl homoserine lactone (AHL) 241, 84, 459, 461 251–253 aminoglycosides 1–3, 76, 84, 86, 88, 93, 97, acyltransfer 83–84 359–361, 373, 376, 453–455, 502 adenosine diphosphate – A-site switch locking in ‘‘on’’ state (ADP)-ribosyltransferase 85 459–461 adriamycin RDF (doxorubicin) 342, 344 – binding affinity and eluding defense AFN-1252 203 mechanisms 461–462 AgrC/AgrA 248–247, 249 – binding pocket recognition 459 agrocin 394, 395 – binding to antibiotic-resistant bacterial ajoene 245, 252, 253 mutant and protozoal cytoplasmic A sites albicidin 275 464 2-alkoxycarbonylaminopyridines 161–164 – binding to human A sites 464–465 amicetin 358, 361, 362 – chemical structures 455 amidases 80 – molecular recognition by bacterial A site amikacin 457, 462, 463 458–459 aminoacyl-tRNA synthetases (aaRSs) 388 – nonaminoglycoside antibiotic targeting of A – classification 389–391 site 466 – enzymatic mechanism of action 388–389 – not targeting A site 465–466 – fidelity and proof reading 391–392 – secondary structures of target A sites 455, – transamidation pathway 392 458 aminoacyl tRNA synthetase inhibitors – semisynthetic aminoglycosides binding 387 463–464 – mupirocin 387, 393–395, 403 – targeting A site with different modes of – novel inhibitors in clinical development action 465 399–403 amphomycin 8, 11 – old and new compounds with aaRS amphotericin B 198 inhibitory activity 393–399 ampicillin 230 – resistance development 403 amycolamicin 281 – selectivity over eukaryotic and mitochondrial AN2690 (tavaborole) 400, 401–402 counterparts 404 anisomycin 361 aminoalkyl pyrimidine carboxamides (AAPCs) ansamycins 15–16, 302–304 44 anthralin 358, 365 Antibiotics: Targets, Mechanisms and Resistance, First Edition.
    [Show full text]
  • Antibacterial Activities and Molecular Docking of Novel Sulfone Biscompound Containing Bioactive 1,2,3-Triazole Moiety
    molecules Article Antibacterial Activities and Molecular Docking of Novel Sulfone Biscompound Containing Bioactive 1,2,3-Triazole Moiety Huda R. M. Rashdan 1,* , Ihsan A. Shehadi 2, Mohamad T. Abdelrahman 3 and Bahaa A. Hemdan 4 1 Chemistry of Natural and Microbial Products Department, Pharmaceutical and Drug Industries Research Division, National Research Centre, Dokki, Cairo 12622, Egypt 2 Chemistry Department, College of Science, University of Sharjah, Sharjah 27272, United Arab Emirates; [email protected] 3 Radioisotopes Department, Nuclear Research Centre, Egyptian Atomic Energy Authority, Cairo 12311, Egypt; [email protected] 4 Water Pollution Research Department, Environmental Research Division, National Research Centre, 33 El Buhouth Street, Cairo 12622, Egypt; [email protected] * Correspondence: [email protected] Abstract: In this study, a new synthetic 1,2,3-triazole-containing disulfone compound was derived from dapsone. Its chemical structure was confirmed using microchemical and analytical data, and it was tested for its in vitro antibacterial potential. Six different pathogenic bacteria were selected. MICs values and ATP levels were determined. Further, toxicity performance was measured using MicroTox Analyzer. In addition, a molecular docking study was performed against two vital enzymes: DNA gyrase and Dihydropteroate synthase. The results of antibacterial abilities showed that the studied synthetic compound had a strong bactericidal effect against all tested bacterial strains, as Citation: Rashdan, H.R.M.; Shehadi, I.A.; Abdelrahman, M.T.; Hemdan, Gram-negative species were more susceptible to the compound than Gram-positive species. Toxicity B.A. Antibacterial Activities and results showed that the compound is biocompatible and safe without toxic impact.
    [Show full text]
  • 6-Veterinary-Medicinal-Products-Criteria-Designation-Antimicrobials-Be-Reserved-Treatment
    31 October 2019 EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use Advice on implementing measures under Article 37(4) of Regulation (EU) 2019/6 on veterinary medicinal products – Criteria for the designation of antimicrobials to be reserved for treatment of certain infections in humans Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. Introduction On 6 February 2019, the European Commission sent a request to the European Medicines Agency (EMA) for a report on the criteria for the designation of antimicrobials to be reserved for the treatment of certain infections in humans in order to preserve the efficacy of those antimicrobials. The Agency was requested to provide a report by 31 October 2019 containing recommendations to the Commission as to which criteria should be used to determine those antimicrobials to be reserved for treatment of certain infections in humans (this is also referred to as ‘criteria for designating antimicrobials for human use’, ‘restricting antimicrobials to human use’, or ‘reserved for human use only’). The Committee for Medicinal Products for Veterinary Use (CVMP) formed an expert group to prepare the scientific report. The group was composed of seven experts selected from the European network of experts, on the basis of recommendations from the national competent authorities, one expert nominated from European Food Safety Authority (EFSA), one expert nominated by European Centre for Disease Prevention and Control (ECDC), one expert with expertise on human infectious diseases, and two Agency staff members with expertise on development of antimicrobial resistance .
    [Show full text]
  • Antibiotic Uptake Across Gram-Negative Outer Membranes: Better Predictions Towards Better Antibiotics
    bioRxiv preprint doi: https://doi.org/10.1101/667006; this version posted June 11, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Antibiotic uptake across gram-negative outer membranes: better predictions towards better antibiotics. Ricardo J. Ferreira† and Peter M. Kasson†‡* † Science for Life Laboratory, Department of Cell and Molecular Biology, Uppsala University, 75124 Uppsala, Sweden ‡ Departments of Biomedical Engineering and Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, VA 22908, USA * E-mail: [email protected]. Address: Box 800886, Charlottesville VA 22908 USA. ABSTRACT: Crossing the gram-negative bacterial membrane poses a major barrier to antibiotic development, as many small molecules that can biochemically inhibit key bacterial processes are rendered microbiologi- cally ineffective by their poor cellular uptake. The outer membrane is the major permeability barrier for many drug-like molecules, and the chemical properties that enable efficient uptake into mammalian cells fail to predict bacterial uptake. We have developed a computational method for accurate prospec- tive prediction of outer-membrane uptake of drug-like molecules, which we combine with a new medi- um-throughput experimental assay. Parallel molecular dynamics simulations are used to successfully and quantitatively predict experimental permeabilities. For most polar molecules we test, outer mem- brane permeability also correlates well with whole-cell uptake. The ability to accurately predict and measure outer-membrane uptake of a wide variety of small molecules will enable simpler determination of which molecular scaffolds and which derivatives are most promising prior to extensive chemical syn- thesis.
    [Show full text]
  • New Aminocoumarin Antibiotics Derived from 4-Hydroxycinnamic
    J. Antibiot. 60(8): 504–510, 2007 THE JOURNAL OF ORIGINAL ARTICLE ANTIBIOTICS New Aminocoumarin Antibiotics Derived from 4-Hydroxycinnamic Acid are Formed after Heterologous Expression of a Modified Clorobiocin Biosynthetic Gene Cluster Christine Anderle, Shu-Ming Li†, Bernd Kammerer, Bertolt Gust, Lutz Heide Received: April 16, 2007/Accepted: July 31, 2007 © Japan Antibiotics Research Association Abstract Three new aminocoumarin antibiotics, termed biosynthesis, cloL (Fig. 1), with the similar couL from ferulobiocin, 3-chlorocoumarobiocin and 8Ј-dechloro-3- coumermycin biosynthesis. couL encodes for an enzyme chlorocoumarobiocin, were isolated from the culture broth with different substrate specificity to CloL [5, 6]. As of a Streptomyces coelicolor M512 strain expressing a expected, the cloQcloL-defective heterologous expression modified clorobiocin biosynthetic gene cluster. Structural strain did not produce clorobiocin. Unexpectedly, however, analysis showed that these new aminocoumarins were very introduction of couL into this strain resulted in the similar to clorobiocin, with a substituted 4-hydroxy- formation of three new aminocoumarin antibiotics. cinnamoyl moieties instead of the prenylated 4-hydroxy- In this paper, we report the isolation, structure benzoyl moiety of clorobiocin. The possible biosynthetic elucidation and antibacterial activities of these three new origin of these moieties is discussed. antibiotics, termed ferulobiocin, 3-chlorocoumarobiocin and 8Ј-dechloro-3-chlorocoumarobiocin. The occurrence of Keywords antibiotics, biosynthesis, clorobiocin, ferulic these compounds has interesting implications for the acid, 3-chloro-4-hydroxycinnamic acid, Streptomyces current hypotheses on phenylpropanoid and amino- coumarin biosynthesis in Streptomycetes. Introduction Materials and Methods Clorobiocin and coumermycin A1 (Fig. 1) are members of the family of aminocoumarin antibiotics. They are potent Strains and Plasmids inhibitors of bacterial gyrase [1] and represent interesting S.
    [Show full text]
  • WO 2010/083148 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 22 July 2010 (22.07.2010) WO 2010/083148 Al (51) International Patent Classification: (74) Agents: GAO, Chuan et al.; Townsend and Townsend Cl 2P 21/00 (2006.01) and Crew LLP, Two Embarcadero Center, 8th Floor, San Francisco, California 941 11 (US). (21) International Application Number: PCT/US20 10/020727 (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, 12 January 2010 (12.01 .2010) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (25) Filing Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (26) Publication Language: English KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (30) Priority Data: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 61/144,401 13 January 2009 (13.01 .2009) US NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (71) Applicant (for all designated States except US): SUTRO TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. BIOPHARMA, INC. [US/US]; 310 Utah Street, Suite 150, South San Francisco, California 94080 (US). (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (72) Inventors; and GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (75) Inventors/Applicants (for US only): VOLOSHIN, Alex- ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, ei M.
    [Show full text]
  • Watching Antibiotics in Action: Exploiting Time-Lapse Microfluidic Microscopy As a Tool for Target-Drug Interaction Studies in Mycobacterium
    bioRxiv preprint doi: https://doi.org/10.1101/477141; this version posted November 23, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Watching antibiotics in action: Exploiting time-lapse microfluidic microscopy as a tool for target-drug interaction studies in Mycobacterium Damian Trojanowski1*, Marta Kołodziej1, Joanna Hołówka1, Rolf Müller2, Jolanta Zakrzewska- Czerwińska1* 1University of Wroclaw, Faculty of Biotechnology, Department of Molecular Microbiology, Wroclaw, Poland, 2German Centre for Infection Research (DZIF), Partner Site Hannover- Braunschweig, Hannover, Germany and Helmholtz Institute for Pharmaceutical Research Saarland, Helmholtz Centre for Infection Research and Department of Pharmacy, Saarland University, Campus E8.1, Saarbrücken, Germany. * Address correspondence to Damian Trojanowski, [email protected] and Jolanta Zakrzewska-Czerwińska, [email protected] Abstract Spreading resistance to antibiotics and the emergence of multidrug-resistant strains have become frequent in many bacterial species, including mycobacteria. The genus Mycobacterium encompasses both human and animal pathogens that cause severe diseases and have profound impacts on global health and the world economy. Here, we used a novel system of microfluidics, fluorescence microscopy and target-tagged fluorescent reporter strains of M. smegmatis to perform real-time monitoring of replisome and chromosome dynamics following the addition of replication- altering drugs (novobiocin, nalidixic acid and griselimycin) at the single-cell level. We found that novobiocin stalled replication forks and caused relaxation of the nucleoid, nalidixic acid triggered rapid replisome collapse and compaction of the nucleoid, and griselimycin caused replisome instability with subsequent over-initiation of chromosome replication and over-relaxation of the nucleoid.
    [Show full text]
  • Front Matter
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY VOLUME 29 * JUNE 1986 * NUMBER 6 Robert C. Moellering, Jr., Editor in Chief (1990) George A. Jacoby, Jr., Editor (1990) New England Deaconess Hospital Massachusetts General Hospital Boston, Mass. Boston Michael Barza, Editor (1990) Christine C. Sanders, Editor (1989) New England Medical Center Hospitals Creighton University School ofMedicine Boston, Mass. Omaha, Neb. Herbert L. Ennis, Editor (1987) John A. Washington II, Editor (1986) Roche Institute ofMolecular Biology Cleveland Clinic Foundation Nutley, N.J. Cleveland, Ohio Jack M. Gwaltney, Jr., Editor (1990) Peter G. Welling, Editor (1988) University of Virginia School ofMedicine Warner-Lambert Co. Charlottesville Ann Arbor, Mich. EDITORIAL BOARD Norris Alien (1986) Gertrude B. Elion (1987) Stuart B. Levy (1986) W. Michael Scheld (1986) Vincent T. Andriole (1987) George M. Eliopoulos (1988) Joan Lusk (1986) Jerome J. Schentag (1988) Bascom F. Anthony (1988) Arthur English (1986) R. Luthy (1986) Raymond F. Schinazi (1986) George R. Aronoff (1986) Robert J. Fass (1988) Gerald L. Mandeli (1986) Fritz D. Schoenknecht (1986) Robert Austrian (1986) Stuart Feldman (1988) Gary R. Matzke (1986) F. C. Sciavolino (1988) Richard H. Baltz (1987) Sydney Finegold (1988) George H. McCracken (1987) William M. Shannon (1986) Rashmi H. Barbhaiya (1986) Robert J. Fitzgerald (1986) Antone A. Medeiros (1987) Charles Shipman, Jr. (1988) Arthur L. Barry (1986) Martin Forbes (1986) Gerald Medoff (1986) David M. Shlaes (1988) John G. Bartlett (1987) Peter T. Frame (1988) Michael Miller (1987) Robert W. Sidweil (1987) Arnold S. Bayer (1988) John N. Galgiani (1987) Thomas P. Moyer (1986) P. Frederick Sparling (1987) William M. Bennett (1987) Dale N.
    [Show full text]